Antimicrobial Agents and Chemotherapy · 2012 · 26 citations · 32 references
Life SciencesBiochemistryMicrobiologyEnzymologyStructural BiologyStructure-activity RelationshipsEnzyme FunctionEnzyme-substrate RecognitionLigand BindingMolecular DockingProtein-ligand DockingStructural EnzymologyAmide HydrolysisBeta-lactamase InhibitorsBeta-lactamase Structure-function RelationshipsNew Delhi Metallo-beta-lactamaseSpectrum Of Beta-lactam AntibioticsSubstrate Binding PocketsSubstrate Binding Sitesβ-Lactam Antibiotics
New Delhi metallo-β-lactamase 1 (NDM-1) is a key enzyme that the pathogen Klebsiella pneumonia uses to hydrolyze almost all β-lactam antibiotics. It is currently unclear why NDM-1 has a broad spectrum of activity. Docking of the representatives of the β-lactam families into the active site of NDM-1 is reported here. All the β-lactams naturally fit the NDM-1 pocket, implying that NDM-1 can accommodate the substrates without dramatic conformation changes. The docking reveals two major binding modes of the β-lactams, which we tentatively name the S (substrate) and I (inhibitor) conformers. In the S conformers of all the β-lactams, the amide oxygen and the carboxylic group conservatively interact with two zinc ions, while the substitutions on the fused rings show dramatic differences in their conformations and positions. Since the bridging hydroxide ion/water in the S conformer is at the position for the nucleophilic attack, the S conformation may simulate the true binding of a substrate to NDM-1. The I conformer either blocks or displaces the bridging hydroxide ion/water, such as in the case of aztreonam, and is thus inhibitory. The docking also suggests that substitutions on the β-lactam ring are required for β-lactams to bind in the S conformation, and therefore, small β-lactams such as clavulanic acid would be inhibitors of NDM-1. Finally, our docking shows that moxalactam uses its tyrosyl-carboxylic group to compete with the S conformer and would thus be a poor substrate of NDM-1.
32
Kanimozhi Kumarasamy, Mark A. Toleman, Timothy R. Walsh et al. · The Lancet Infectious Diseases · 2010 · 2.9K citations · Full text
Dongeun Yong, Mark A. Toleman, Christian G. Giske et al. · Antimicrobial Agents and Chemotherapy · 2009 · 2.4K citations · Full text
A semiempirical free energy force field with charge‐based desolvation
Ruth Huey, Garrett M. Morris, Arthur J. Olson et al. · Journal of Computational Chemistry · 2007 · 2.2K citations · Full text